Last reviewed · How we verify
NCT03938025
Impact of Resected Gastric Volume on Postoperative Weight Loss After Laparoscopic Sleeve Gastrectomy for Morbid Obesity
trial testing Gastric volume resected in sleeve gastrectomy in Morbid Obesity in 92 participants. Completed in 30 April 2019.
1 January 2017
Quick facts
| Lead sponsor | University of Rome Tor Vergata |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 92 |
| Start date | 1 January 2013 |
| Primary completion | 1 January 2017 |
| Estimated completion | 30 April 2019 |
Drugs / interventions tested
- Gastric volume resected in sleeve gastrectomy
Conditions studied
- Morbid Obesity — all drugs for Morbid Obesity →
Sponsor
University of Rome Tor Vergata
Who can join
Adults 18 to 70, any sex, with Morbid Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Impact of resected gastric volume on postoperative weight loss after laparoscopic sleeve gastrectomy for morbid obesity. Observational study with a mathematical method to approximate the calculation of the resected gastric volume after a sleeve gastrectomy and see the outcome on weight loss.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of Resected Gastric Volume on Postoperative Weight Loss after Laparoscopic Sleeve Gastrectomy.
D'Ugo S, Bellato V, Bianciardi E, Gentileschi P. · · 2019 · cited 8× · PMID 31871448 · DOI 10.1155/2019/3742075
Verify or expand the search:
- PubMed search for NCT03938025
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Morbid Obesity
Currently open trials in the same condition.
- NCT06689241 — Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery · NA · recruiting
- NCT06413264 — Ultrasonography Guided Pneumoperitoneum for Laparoscopic Surgery in Morbidly Obese Patients · NA · recruiting
- NCT07289555 — Tailored Stapled SADI-S: Initial Report and Preliminary Results · NA · recruiting
- NCT07263269 — Comparing Dumping Symptoms and Quality of Life 6 Months After Sleeve Gastrectomy With or Without Transit Bipartition in · NA · active not recruiting
- NCT06293703 — Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study) · NA · recruiting
Other University of Rome Tor Vergata trials
Trials by the same sponsor.
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT07313358 — 10119473 -VIROMARKERS HDV Biomarkers Study · not yet recruiting
- NCT07286461 — VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol · not yet recruiting
- NCT07067749 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer · Phase 3 · recruiting
- NCT06711744 — ISQ Differences Between Different Implants in Post-extraction Sockets · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03938025 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rome Tor Vergata
- Last refreshed: 7 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03938025.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing